



Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: correspondence

Rujittika Mungmunpantipanjtip¹ · Won Sriwijitalai² · Viroj Wiwanitkit³

Received: 10 August 2022 / Accepted: 14 August 2022 / Published online: 31 August 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

To the editor,

We'd like to discuss the article "Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study [1]." This study found that the total seroconversion rate following the second vaccination was 95.3%, with chemotherapy patients having the lowest seroconversion rate at 81.8% [1]. The data support SARS-CoV-2 vaccination for breast cancer patients, according to Terada et al. [1]; nevertheless, a possible decrease in neutralizing antibody titers after chemotherapy and CDK4/6 inhibitors has raised questions about the influence on long-term infection prevention. But it's critical to keep an eye out for circumstances that are more challenging. Before the vaccine, a COVID could have occurred, which would have impacted subsequent immunity. Asymptomatic COVID-19 infection is typically not unusual [2]. In the absence of any symptoms, a history of infection cannot rule out previous COVID-19, and the results can be misleading. Even while a single history of infection may not be enough to rule out COVID-19 in the absence of symptoms, it is typically required for the accurate interpretation of a vaccination schedule.

Funding None.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This is not study on human/animal study and requires no ethical approval or informed consent.

References

1. Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Akiko K, Yamanaka N, Sugiura H, Mita K, Wada A, Takahashi E, Saito K, Yoshioka R, Toyama T (2022) Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. *Breast Cancer Res Treat.* <https://doi.org/10.1007/s10549-022-06693-2>
2. Joob B, Wiwanitkit V (2020) Letter to the Editor: Coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. *J Prev Med Public Health* 53(2):70

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Rujittika Mungmunpantipanjtip
rujittika@gmail.com

Won Sriwijitalai
drwonsriwijit@gmail.com

¹ Bangkok, Thailand

² Dimapur, India

³ Dr DY Patil University, Pune, India